Ulcerative proctitis - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Ulcerative proctitis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Ulcerative proctitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Ulcerative proctitis: Overview
Ulcerative proctitis is a mild form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. In this form of colitis, the inflammation begins at the rectum, and spreads no more than about 20 cm (7-8?) into the colon. About 25-30% of those diagnosed with ulcerative colitis might actually have ulcerative proctitis. The cause of ulcerative proctitis is undetermined but there is considerable research evidence to suggest that interactions between environmental factors, intestinal flora, immune dysregulation, and genetic predisposition are responsible. It is unclear why the inflammation is limited to the rectum. There is a slightly increased risk for those who have a family member with the condition.
'Ulcerative proctitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ulcerative proctitis pipeline landscape is provided which includes the disease overview and Ulcerative proctitis treatment guidelines. The assessment part of the report embraces, in depth Ulcerative proctitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative proctitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Ulcerative proctitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative proctitis Emerging Drugs
Further product details are provided in the report.
Ulcerative proctitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative proctitis drugs segregated based on following parameters that define the scope of the report, such as:
Ulcerative proctitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ulcerative proctitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative proctitis drugs.
Ulcerative proctitis Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Ulcerative proctitis - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Ulcerative proctitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Ulcerative proctitis: Overview
Ulcerative proctitis is a mild form of ulcerative colitis, a chronic inflammatory bowel disease (IBD) consisting of fine ulcerations in the inner mucosal lining of the large intestine that do not penetrate the bowel muscle wall. In this form of colitis, the inflammation begins at the rectum, and spreads no more than about 20 cm (7-8?) into the colon. About 25-30% of those diagnosed with ulcerative colitis might actually have ulcerative proctitis. The cause of ulcerative proctitis is undetermined but there is considerable research evidence to suggest that interactions between environmental factors, intestinal flora, immune dysregulation, and genetic predisposition are responsible. It is unclear why the inflammation is limited to the rectum. There is a slightly increased risk for those who have a family member with the condition.
'Ulcerative proctitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ulcerative proctitis pipeline landscape is provided which includes the disease overview and Ulcerative proctitis treatment guidelines. The assessment part of the report embraces, in depth Ulcerative proctitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ulcerative proctitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative proctitis R&D. The therapies under development are focused on novel approaches to treat/improve Ulcerative proctitis.
This segment of the Ulcerative proctitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ulcerative proctitis Emerging Drugs
- FW 424: First Wave Bio
- Budesonide suppository: Dr Falk Pharma
Further product details are provided in the report.
Ulcerative proctitis: Therapeutic Assessment
This segment of the report provides insights about the different Ulcerative proctitis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Ulcerative proctitis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Ulcerative proctitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ulcerative proctitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative proctitis drugs.
Ulcerative proctitis Report Insights
- Ulcerative proctitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Ulcerative proctitis drugs?
- How many Ulcerative proctitis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ulcerative proctitis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative proctitis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ulcerative proctitis and their status?
- What are the key designations that have been granted to the emerging drugs?
- First Wave Bio
- Dr Falk Pharma
- Alfasigma
- Cristcot LLC
- FW 424
- Budesonide suppository
- Brilacidin
- hydrocortisone acetate suppository
Introduction
Executive Summary
Ulcerative proctitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ulcerative proctitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ulcerative proctitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ulcerative proctitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Budesonide suppository: Dr Falk Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I/II)
Comparative Analysis
FW 424: First Wave Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Ulcerative proctitis Key Companies
Ulcerative proctitis Key Products
Ulcerative proctitis- Unmet Needs
Ulcerative proctitis- Market Drivers and Barriers
Ulcerative proctitis- Future Perspectives and Conclusion
Ulcerative proctitis Analyst Views
Ulcerative proctitis Key Companies
Appendix
Executive Summary
Ulcerative proctitis: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Ulcerative proctitis – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Ulcerative proctitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Ulcerative proctitis Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Budesonide suppository: Dr Falk Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Early Stage Products (Phase I/II)
Comparative Analysis
FW 424: First Wave Bio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Ulcerative proctitis Key Companies
Ulcerative proctitis Key Products
Ulcerative proctitis- Unmet Needs
Ulcerative proctitis- Market Drivers and Barriers
Ulcerative proctitis- Future Perspectives and Conclusion
Ulcerative proctitis Analyst Views
Ulcerative proctitis Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Ulcerative proctitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Ulcerative proctitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Ulcerative proctitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Ulcerative proctitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products